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Commentary
The Integrated Project DRUID (Driving under the Influence of
Drugs, Alcohol andMedicines) involved researchers frommore
than 20 European countries. It aimed to gain new insights to the
degree of impairment caused by psychoactive drugs and their
actual impact on road safety. Part of this large research program
that was conducted between 2006 and 2011 has been devoted to
the assessment of stimulant drug effects on driving performance
in experimental, placebo-controlled studies. These studies are
presented in the current issue of psychopharmacology and
focus on single-dose effects of MDMA (Bosker et al. 2012)
and dexamphetamine (Hjalmdahl et al. 2012) on driving
performance before and after a night of sleep deprivation and
on the effects of MDMA (Veldstra et al. 2012) and dexamphet-
amine (Simons et al. 2012) with and without alcohol. The major
objective of these studies was to provide scientific basis for
harmonized pan-European regulations of driving under the
influence (DUI) of stimulants. Research partners agreed on a
number of standardized driving scenarios to increase compara-
bility between studies. These included a road tracking test to
measure standard deviation of lateral position (SDLP) or “weav-
ing motion” during prolonged highway driving (O'Hanlon et al.
1982), a car-following scenario to measure a driver's ability to
adapt to maneuvers of other motorists (Brookhuis and deWaard
1993; Ramaekers and O'Hanlon 1994), and in case of driving
simulator studies, risk-taking scenarios. In addition, all partners
included a number of laboratory tests measuring skills related to
driving. These tests included tracking tasks, attention tasks,
reaction tasks, and cognitive tasks. Significant drug effects were
statistically evaluated for clinical relevance by equiva-
lence testing. Equivalence testing of drug effects was
based on difference in scores from placebo relative to
an alcohol criterion (i.e., equivalence to a blood alcohol
concentration (BAC) of 0.5 mg/mL). Basically, equiva-
lence testing assessed whether the alcohol criterion val-
ue falls within the 95 % confidence interval (CI) for the
drug effect. If yes, then the drug effect was considered equiv-
alent to a BAC of 0.05 mg/mL (and thus clinically relevant for
traffic safety). If the 95 % CI was below the alcohol criterion
value, then a drug effect was considered not relevant. An
integrative overview of results from the four experimental
studies is presented in Tables 1 and 2.
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Effects of MDMA and dexamphetamine
The effects of MDMA and dexamphetamine on measures of
simulated and actual driving were neutral for most of the
driving measures or even positive for specific measures (i.e.,
road tracking). Stimulatory effects were also supported by
subjective data that indicated that MDMA and dexamphet-
amine increased arousal and decreased sleepiness. The
stimulatory effects of stimulants on human performance
have been widely acknowledged (Ramaekers et al. 2006;
Kuypers et al. 2006), and as such are no real surprise. It
should be noted, however, that previous research had also
demonstrated that stimulant drugs can improve certain
aspects of performance while impairing other performance
domains at the same time. For example, stimulants have
repeatedly been shown to improve neuropsychological
skills, such as tracking, impulse control, and reaction time,
while impairing cognitive functions such as working mem-
ory and movement perception (Kuypers and Ramaekers 2005;
Lamers et al. 2003; Silber et al. 2006, 2005; Ramaekers et al.
2009). Thus, the finding that MDMA and dexamphet-
amine can improve performance in particular driving
domains does not automatically mean that these drugs
do never have detrimental effects in other domains relevant to
driving as well.
Effects of alcohol alone and combination with MDMA
and dexamphetamine
Alcohol was administered in two simulated driving studies in
order to assess the potential interaction between alcohol–
MDMA and alcohol–dexamphetamine. Alcohol significantly
impaired road tracking performance in the study by Simons
et al. (2012). Coadministration of dexamphetamine did not
significantly change the impairing effect of alcohol as evinced
by the lack of statistical interaction between dexamphetamine
and alcohol. Equivalence testing demonstrated that the 95 %
CI of the change in road tracking performance (i.e., SDLP)
after combined use of dexamphetamine and alcohol included
both the alcohol criterion as well as the placebo reference
(zero). The latter basically means that the evaluation of the
clinical relevance of the combined effects of dexamphetamine
and alcohol are undecided or ambiguous, i.e., it is predicted
that some individuals will show impairment, whereas others
may not.
Risk scenarios and secondary driving measures employed
by Simons et al. (2012) were very sensitive to the effects of
alcohol alone and to alcohol–dexamphetamine combined.
These measures demonstrated that single doses of alcohol
(0.8 g/kg body weight) increased risk-taking behaviors (i.e.,
shorter gap acceptance, increase of red light crossings, and
number of crashes) and impaired tracking, attention, and
reaction time during a 3-h period after drinking when BACs
declined from 0.9 to 0.2 mg/mL. Moreover, these alcohol
impairments were not affected by the coadministration of
dexamphetamine 20mg, indicating that the stimulatory effects
of dexamphetamine were not sufficient to overcome the
impairing effects of alcohol on skills related to driving.
Alcohol effects were most prominent in the road tracking
scenario in theMDMA–alcohol interaction study conducted by
Veldstra et al. (2012). As expected, alcohol significantly in-
creased SDLP or the amount of “weaving” during highway
driving, suggesting a decrement of road tracking control. This
finding nicely replicates earlier demonstration of alcohol-
induced impairment of road tracking performance in actual,
on-the-road driving test scenarios (Kuypers et al. 2006;
Louwerens et al. 1987). Average BACs during the simulated
driving tests were around 0.45–0.50 mg/mL during treatments
with alcohol. The stimulatory effects ofMDMA (100mg) were
sufficient to counteract some of the impairing effects of this
low dose of alcohol on SDLP as indicated by a significant
MDMA × alcohol interaction. However, equivalence tests
again demonstrated that change in SDLP after the combination
of MDMA and alcohol included both the alcohol criterion as
well as the placebo reference. In other words, due to large
variation in subject sensitivity to combination of MDMA and
alcohol, some subjects showed impairment, whereas others did
not. These findings are in line with previous research that also
indicated that stimulatory effects of MDMA are not sufficient
to fully overcome alcohol-induced impairments of driving
performance, psychomotor function, and cognition (Kuypers
et al. 2006; Brookhuis et al. 2004; Dumont et al. 2008; Kuypers
et al. 2006; Ramaekers and Kuypers 2006; Hernandez-Lopez
et al. 2002).
Effects of sleep deprivation with or without MDMA
or dexamphetamine
The sleep deprivation studies demonstrated that sleep loss
produced severe impairment in actual and simulated driving
performance as expressed by a significant rise in SDLP in the
road tracking scenario. In the on-the-road driving study
(Bosker et al. 2012), a large number of driving tests were
prematurely terminated due to excessive fatigue.
On average, SDLP increased with 4.2 cm in the morning
after sleep deprivation, relative to SDLP before sleep depri-
vation. This increment is about 1.5–2 times greater than that
found in two recent driving under the influence of alcohol
studies with blood alcohol concentrations between 0.29 and
0.5 mg/mL (Kuypers et al. 2006). From a previous alcohol
study that was conducted in order to calibrate SDLP for the
dose-related effects of alcohol (Louwerens et al. 1987), it can
be concluded that a mean increase in SDLP of 4.2 cm is
equivalent to a blood alcohol concentration of approximately
0.8 mg/mL. Equivalence testing even demonstrated that the
upper limit of the 95 % CI associated with the mean change in
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SDLP after sleep deprivation widely exceeded the criterion
level of 1.0 mg/mL BAC. These findings were corroborated
by results from secondary driving measures as measured in
laboratory tests. Critical tracking performance significantly
decreased over the night, as a function of hours of sleep loss.
Together, this indicates that sleep deprivation caused severe
driving impairment comparable to driving under the influence
of high to very high BAC.
It is also apparent from the present studies that the stimulant
effects of MDMA and dexamphetamine, if any, could not
compensate for the impairing effect of sleep loss on simulated
and actual driving performance. None of the primary driving
measures demonstrated any significant MDMA × sleep loss
interaction. The effects of sleep deprivation on driving
were highly prominent during MDMA and dexamphet-
amine treatments and did not change as a function of dose and
concentration.
Concentration effect relations of MDMA
and dexamphetamine
Two studies were specifically designed to assess driving per-
formance across a wide range of doses and concentrations.
The MDMA–sleep deprivation study (Bosker et al. 2012)
included three doses of MDMA (25, 50, and 100 mg), where-
as the dexamphetamine–sleep deprivation study included a
low dose (10mg) and a high dose (40mg) of dexamphetamine
(Hjalmdahl et al. 2012). It was apparent in both studies that
neither MDMA nor dexamphetamine produced any dose- or
concentration-related effects on driving. Also, the inability of
both stimulants to compensate for the impairing effects of
alcohol and sleep deprivation was not affected by dose or
concentration.
It should, however, be noted that doses administered in the
present studies may have been relatively low for (some) recre-
ational drug users. Dexamphetamine doses (10–40 mg) were
well with the accepted therapeutic window when used for
medical purposes. Likewise, MDMA doses were close to the
amount of MDMA that is generally present in a single ecstasy
tablet (i.e., 50–100 mg). However, it is very likely that a
significant proportion of recreational drug users will take much
higher doses of dexamphetamine and MDMA in real-life sit-
uations. High-dose effects of stimulant on driving performance
cannot be readily assessed in experimental, placebo-controlled
studies due to obvious medical and ethical constraints. It has
become evident, however, that MDMA and amphetamine
concentrations that are observed in actual DUI cases can be
10-fold higher than during controlled administration in exper-
imental studies. A recent study analyzing drug concentrations
in postmortem cases and DUI cases in the Netherlands in
1999–2004 may serve to illustrate this point (Verschraagen et
al. 2007). Amphetamine-based drugs were present in 70 post-
mortem cases and 467 DUI cases. The most detected
amphetamine-based drug was MDMA, followed by amphet-
amine. Median blood concentrations of MDMA in postmor-
tem and DUI cases were 1,600 and 330 ng/mL, respectively.
MDMA blood concentrations in the MDMA-related deaths
(n020) and in the DUI cases (n0360) varied up to 3,700 and
4,000 ng/mL, respectively. The median concentrations of am-
phetamine in the amphetamine-related deaths (n013) and the
DUI cases (n0208) were 280 and 220 ng/mL, respectively.
Amphetamine blood concentrations up to 6,000 and 2,300
ng/mL were seen in the drug-related deaths and DUI cases,
respectively. The most frequently encountered amphetamine-
based drugs in the investigated deaths were MDMA and
amphetamine. The majority of MDMA- and amphetamine-
caused deaths, i.e., 90 % of these deaths, occurred with blood
concentrations above 1,500 and 800 ng/mL, respectively.
Clearly, these data show that amphetamine concentrations in
DUI cases can be much higher than amphetamine concentra-
tions that are achieved in controlled studies.
MDMA, dexamphetamine, and driving safety
The pharmacological effects of stimulants and drug use set-
tings seem very much intertwined and are likely to play a
crucial role when evaluating driving under the influence
offenders. Some will take the present data as an argument to
show that the primary reason for impairment observed in DUI
cases with stimulants will be sleep deprivation or concomitant
use of alcohol and drugs. Others can argue that the use of
stimulants may affect a person's ability to subjectively evaluate
or recognize their state of impairment. Stimulants increase
subjective feelings of arousal, energy, and mood. Such feelings
affect the subjective judgment of stimulant users on whether or
not it is safe to drive home after spending a night at a rave party.
During intoxication with a stimulant, they may not be able to
subjectively experience the debilitating effects of sleep loss or
concomitant alcohol use to the same degree as stimulant-free
drivers, because they feel more energetic. As a consequence,
they may decide to drive because they subjectively feel alert
while neglecting the objectively impairing effects of other
cofactors, such as sleep deprivation or alcohol use.
In the context of a pan-European initiative to combat
driving under the influence of drugs, it is advised to distin-
guish between (1) potential medicinal use of amphetamines
(therapeutic doses) and (2) drug abuse of stimulants (poly-
pharmacy and combat of sleep). Stimulants are generally safe
for driving when taken alone at regular doses (e.g., as in
medicinal use), but stimulant effects are less safe when taken
in combination with sleep loss or alcohol intoxication as is
often the case in drug abusers. In such cases, it will be very
difficult to separate stimulant effects from those of drug use
setting. Consequently, drivers should receive specific warn-
ings on driving impairment arising from the use of stimulants
during sleep loss or alcohol intoxication.
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